Beating a dead horse: Dopamine and parkinson disease: Reply

Neurology

Volumn 71, Issue 20, 2008, Pages 1651-1652

  Ahlskog, J Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; LEVODOPA; DOPAMINE; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT;

BRAIN DEPTH STIMULATION; DRUG RESPONSE; DYSKINESIA; HUMAN; LETTER; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; CLINICAL TRIAL; DISABILITY; DOPAMINERGIC SYSTEM; LONG TERM CARE; NERVE CELL; NEUROPROTECTION; METABOLISM; NOTE;

DOPAMINE; DOPAMINE AGENTS; HUMANS; PARKINSON DISEASE;

EID: 58149388332     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000339368.54460.68     Document Type: Letter

References (8)

1. Ahlskog JE. Beating a dead horse: dopamine and Parkinson disease. Neurology 2007;69:1701-1711.
2. The Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351: 2498-2508.
3. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976 -1990. Arch Neurol 2006;63:205-209.
4. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
5. Ahlskog J, Meunter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
6. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781.
7. de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004; 127:888-899.
8. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986;19:365-372.